Antibiotic resistance: a rundown of a global crisis

Infection and Drug Resistance

Volumn 11, Issue , 2018, Pages 1645-1658

  Aslam, Bilal ^a   Wang, Wei ^b   Arshad, Muhammad Imran ^c   Khurshid, Mohsin ^a   Muzammil, Saima ^a   Rasool, Muhammad Hidayat ^a   Nisar, Muhammad Atif ^a   Alvi, Ruman Farooq ^a   Aslam, Muhammad Aamir ^c   Qamar, Muhammad Usman ^a   Salamat, Muhammad Khalid Farooq ^d   Baloch, Zulqarnain ^e  

^a GOVERNMENT COLLEGE UNIVERSITY   (Pakistan)

^b CHINA NATIONAL CENTER FOR FOOD SAFETY RISK ASSESSMENT   (China)

^c UNIVERSITY OF AGRICULTURE   (Pakistan)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

^e SOUTH CHINA AGRICULTURAL UNIVERSITY   (China)

Author keywords

Alternative therapies; Antibiotics; Evolution; Multidrug resistance

Indexed keywords

ANTIBIOTIC AGENT; ANTIBODY; PROBIOTIC AGENT; VACCINE;

AGRICULTURE; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERIAL VIRULENCE; BACTERIUM; ENVIRONMENT; FINANCIAL MANAGEMENT; GOVERNMENT REGULATION; HEALTH CARE; HUMAN; INFECTION PREVENTION; MEDICINE; MICROBIOLOGICAL EXAMINATION; MULTIDRUG RESISTANCE; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PSEUDOMONAS AERUGINOSA; REVIEW; STAPHYLOCOCCUS AUREUS;

EID: 85057588971     PISSN: None     EISSN: 11786973     Source Type: Journal    
DOI: 10.2147/IDR.S173867     Document Type: Review

References (137)

1. Singer AC, Shaw H, Rhodes V, Hart A. Review of antimicrobial resistance in the environment and its relevance to environmental regulators. Front Microbiol. 2016;7:1728.
2. Marshall BM, Levy SB. Food animals and antimicrobials: impacts on human health. Clin Microbiol Rev. 2011;24(4):718–733.
3. Nathan C, Cars O. Antibiotic resistance-problems, progress, and prospects. N Engl J Med. 2014;371(19):1761–1763.
4. Nathan C. Antibiotics at the crossroads. Nature. 2004;431(7011): 899–902.
5. Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev. 2010;74(3):417–433.
6. van Boeckel TP, Brower C, Gilbert M, et al. Global trends in antimicrobial use in food animals. Proc Natl Acad Sci U S A. 2015;112(18): 5649–5654.
7. Roca I, Akova M, Baquero F, et al. The global threat of antimicrobial resistance: science for intervention. New Microbes New Infect. 2015;6:22–29.
8. Rossolini GM, Arena F, Pecile P, Pollini S. Update on the antibiotic resistance crisis. Curr Opin Pharmacol. 2014;18:56–60.
9. Michael CA, Dominey-Howes D, Labbate M. The antimicrobial resistance crisis: causes, consequences, and management. Front Public Health. 2014;2:145.
10. Spellberg B, Srinivasan A, Chambers HF. New societal approaches to empowering antibiotic stewardship. JAMA. 2016;315(12):1229–1230.
11. Hoffman SJ, Caleo GM, Daulaire N, et al. Strategies for achieving global collective action on antimicrobial resistance. Bull World Health Organ. 2015;93(12):867–876.
12. Payne DJ, Miller LF, Findlay D, Anderson J, Marks L. Time for a change: addressing R&D and commercialization challenges for antibacterials. Philos Trans R Soc Lond B Biol Sci. 2015;370(1670):20140086.
13. Luepke KH, Mohr JF. The antibiotic pipeline: reviving research and development and speeding drugs to market. Expert Rev Anti Infect Ther. 2017;15(5):425–433.
14. Landers T, Kavanagh KT. Is the Presidential Advisory Council on Combating Antibiotic Resistance missing opportunities? Am J Infect Control. 2016;44(11):1356–1359.
15. Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. P T. 2015;40(4):277–283.
16. Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. Pathog Glob Health. 2015;109(7): 309–318.
17. Laxminarayan R, Duse A, Wattal C, et al. Antibiotic resistance-the need for global solutions. Lancet Infect Dis. 2013;13(12):1057–1098.
18. Guidos RJ. Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis. 2011;52(Suppl 5):S397–S428.
19. Gould IM, Bal AM. New antibiotic agents in the pipeline and how they can help overcome microbial resistance. Virulence. 2013;4(2):185–191.
20. Bartlett JG, Gilbert DN, Spellberg B. Seven ways to preserve the miracle of antibiotics. Clin Infect Dis. 2013;56(10):1445–1450.
21. Economou V, Gousia P. Agriculture and food animals as a source of antimicrobial-resistant bacteria. Infect Drug Resist. 2015;8:49–61.
22. Maron DF, Smith TJ, Nachman KE. Restrictions on antimicrobial use in food animal production: an international regulatory and economic survey. Global Health. 2013;9:48.
23. Founou LL, Founou RC, Essack SY. Antibiotic resistance in the food chain: a developing country-perspective. Front Microbiol. 2016;7:1881.
24. Sengupta S, Chattopadhyay MK, Grossart HP. The multifaceted roles of antibiotics and antibiotic resistance in nature. Front Microbiol. 2013;4:47.
25. Piddock LJ. The crisis of no new antibiotics – what is the way forward? Lancet Infect Dis. 2012;12(3):249–253.
26. Spellberg B, Gilbert DN. The future of antibiotics and resistance: a tribute to a career of leadership by John Bartlett. Clin Infect Dis. 2014;59(Suppl 2):S71–S75.
27. Wright GD. Something old, something new: revisiting natural products in antibiotic drug discovery. Can J Microbiol. 2014;60(3):147–154.
28. Holmes AH, Moore LS, Sundsfjord A, et al. Understanding the mechanisms and drivers of antimicrobial resistance. Lancet. 2016;387(10014):176–187.
29. Forsberg KJ, Patel S, Gibson MK, et al. Bacterial phylogeny structures soil resistomes across habitats. Nature. 2014;509(7502):612–616.
30. Aminov RI. The role of antibiotics and antibiotic resistance in nature. Environ Microbiol. 2009;11(12):2970–2988.
31. Martinez JL. The role of natural environments in the evolution of resistance traits in pathogenic bacteria. Proc Biol Sci. 2009;276(1667):2521–2530.
32. Andersson DI, Hughes D. Microbiological effects of sublethal levels of antibiotics. Nat Rev Microbiol. 2014;12(7):465–478.
33. Morita Y, Tomida J, Kawamura Y. Responses of Pseudomonas aeruginosa to antimicrobials. Front Microbiol. 2014;4:422.
34. Khurshid M, Rasool MH, Ashfaq UA, Aslam B, Waseem M. Emergence of ISAba1 harboring carbapenem-resistant Acinetobacter baumannii isolates in Pakistan. Future Microbiol. 2017;12:1261–1269.
35. Read AF, Woods RJ. Antibiotic resistance management. Evol Med Public Health. 20142014;147(1).
36. Lushniak BD. Antibiotic resistance: a public health crisis. Public Health Rep. 2014;129(4):314–316.
37. Munita JM, Arias CA. Mechanisms of antibiotic resistance. Microbiol Spectr. 2016;4(2).
38. Stokes HW, Gillings MR. Gene flow, mobile genetic elements and the recruitment of antibiotic resistance genes into Gram-negative pathogens. FEMS Microbiol Rev. 2011;35(5):790–819.
39. Wellington EM, Boxall AB, Cross P, et al. The role of the natural environment in the emergence of antibiotic resistance in Gram-negative bacteria. Lancet Infect Dis. 2013;13(2):155–165.
40. Lewis DA. The role of core groups in the emergence and dissemination of antimicrobial-resistant N. gonorrhoeae. Sex Transm Infect. 2013;89(Suppl 4):47–51.
41. Chamchod F, Ruan S. Modeling methicillin-resistant Staphylococcus aureus in hospitals: transmission dynamics, antibiotic usage and its history. Theor Biol Med Model. 2012;9:25.
42. Anderson ES, Lewis MJ. Drug resistance and its transfer in Salmonella typhimurium. Nature. 1965;206(984):579–583.
43. Molbak K. Spread of resistant bacteria and resistance genes from animals to humans – the public health consequences. J Vet Med B Infect Dis Vet Public Health. 2004;51(8–9):364–369.
44. Humphrey TJ, Jorgensen F, Frost JA, et al. Prevalence and subtypes of ciprofloxacin-resistant Campylobacter spp. in commercial poultry flocks before, during, and after treatment with fluoroquinolones. Antimicrob Agents Chemother. 2005;49(2):690–698.
45. Kristiansson E, Fick J, Janzon A, et al. Pyrosequencing of antibiotic-contaminated river sediments reveals high levels of resistance and gene transfer elements. PLoS One. 2011;6(2):e17038.
46. Shah NS, Wright A, Bai GH, et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis. 2007;13(3):380–387.
47. Sotgiu G, Ferrara G, Matteelli A, et al. Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur Respir J. 2009;33(4):871–881.
48. Deleo FR, Chambers HF. Reemergence of antibiotic-resis-tant Staphylococcus aureus in the genomics era. J Clin Invest. 2009;119(9):2464–2474.
49. Watkins RR, David MZ, Salata RA. Current concepts on the virulence mechanisms of methicillin-resistant Staphylococcus aureus. J Med Microbiol. 2012;61(Pt 9):1179–1193.
50. Beceiro A, Tomas M, Bou G. Antimicrobial resistance and virulence: a successful or deleterious association in the bacterial world? Clin Microbiol Rev. 2013;26(2):185–230.
51. Martinez JL, Baquero F. Interactions among strategies associated with bacterial infection: pathogenicity, epidemicity, and antibiotic resistance. Clin Microbiol Rev. 2002;15(4):647–679.
52. Fair RJ, Tor Y. Antibiotics and bacterial resistance in the 21st century. Perspect Medicin Chem. 2014;6:25–64.
53. Feldman MW, Laland KN. Gene-culture coevolutionary theory. Trends Ecol Evol. 1996;11(11):453–457.
54. Burrus V, Waldor MK. Shaping bacterial genomes with integrative and conjugative elements. Res Microbiol. 2004;155(5):376–386.
55. Handel A, Regoes RR, Antia R. The role of compensatory mutations in the emergence of drug resistance. PLoS Comput Biol. 2006;2(10):e137.
56. Patel R. Biofilms and antimicrobial resistance. Clin Orthop Relat Res. 2005;437:41–47.
57. Seral C, van Bambeke F, Tulkens PM. Quantitative analysis of genta-micin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages. Antimicrob Agents Chemother. 2003;47(7):2283–2292.
58. Tsai YK, Fung CP, Lin JC, et al. Klebsiella pneumoniae outer membrane porins OmpK35 and OmpK36 play roles in both antimicrobial resistance and virulence. Antimicrob Agents Chemother. 2011;55(4):1485–1493.
59. Moya B, Juan C, Alberti S, Perez JL, Oliver A. Benefit of having multiple ampD genes for acquiring beta-lactam resistance without losing fitness and virulence in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2008;52(10):3694–3700.
60. Yeung AT, Bains M, Hancock RE. The sensor kinase CbrA is a global regulator that modulates metabolism, virulence, and antibiotic resistance in Pseudomonas aeruginosa. J Bacteriol. 2011;193(4): 918–931.
61. Lye DC, Earnest A, Ling ML, et al. The impact of multidrug resistance in healthcare-associated and nosocomial Gram-negative bacteraemia on mortality and length of stay: cohort study. Clin Microbiol Infect. 2012;18(5):502–508.
62. Sohail M, Rashid A, Aslam B, et al. Antimicrobial susceptibility of Acinetobacter clinical isolates and emerging antibiogram trends for nosocomial infection management. Rev Soc Bras Med Trop. 2016;49(3):300–304.
63. Blair JM, Webber MA, Baylay AJ, Ogbolu DO, Piddock LJ. Molecular mechanisms of antibiotic resistance. Nat Rev Microbiol. 2015;13(1):42–51.
64. Voulgari E, Poulou A, Koumaki V, Tsakris A. Carbapenemase-producing Enterobacteriaceae: now that the storm is finally here, how will timely detection help us fight back? Future Microbiol. 2013;8(1):27–39.
65. Johnson AP, Woodford N. Global spread of antibiotic resistance: the example of New Delhi metallo-beta-lactamase (NDM)-mediated carbapenem resistance. J Med Microbiol. 2013;62(Pt 4): 499–513.
66. Woodford N, Turton JF, Livermore DM. Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. FEMS Microbiol Rev. 2011;35(5):736–755.
67. Lynch JP 3rd, Clark NM, Zhanel GG. Evolution of antimicrobial resistance among Enterobacteriaceae (focus on extended spectrum beta-lactamases and carbapenemases). Expert Opin Pharmacother. 2013;14(2):199–210.
68. Chuanchuen R, Karkhoff-Schweizer RR, Schweizer HP. High-level triclosan resistance in Pseudomonas aeruginosa is solely a result of efflux. Am J Infect Control. 2003;31(2):124–127.
69. Zhu L, Lin J, Ma J, Cronan JE, Wang H. Triclosan resistance of Pseudomonas aeruginosa PAO1 is due to FabV, a triclosan-resistant enoyl-acyl carrier protein reductase. Antimicrob Agents Chemother. 2010;54(2):689–698.
70. Randall CP, Mariner KR, Chopra I, O’Neill AJ. The target of daptomy-cin is absent from Escherichia coli and other Gram-negative pathogens. Antimicrob Agents Chemother. 2013;57(1):637–639.
71. Blake KL, O’Neill AJ. Transposon library screening for identification of genetic loci participating in intrinsic susceptibility and acquired resistance to antistaphylococcal agents. J Antimicrob Chemother. 2013;68(1):12–16.
72. Liu A, Tran L, Becket E, et al. Antibiotic sensitivity profiles determined with an Escherichia coli gene knockout collection: generating an antibiotic bar code. Antimicrob Agents Chemother. 2010;54(4):1393–1403.
73. Floyd JL, Smith KP, Kumar SH, Floyd JT, Varela MF. LmrS is a multidrug efflux pump of the major facilitator superfam-ily from Staphylococcus aureus. Antimicrob Agents Chemother. 2010;54(12):5406–5412.
74. Rm H, Liao ST, Huang CC, Huang YW, Yang TC. An inducible fusaric acid tripartite efflux pump contributes to the fusaric acid resistance in Stenotrophomonas maltophilia. PLoS One. 2012;7(12):e51053.
75. Kim C, Mwangi M, Chung M, Milheirico C, de Lencastre H, Tomasz A. The mechanism of heterogeneous beta-lactam resistance in MRSA: key role of the stringent stress response. PLoS One. 2013;8(12):e82814.
76. Ogawa W, Onishi M, Ni R, Tsuchiya T, Kuroda T. Functional study of the novel multidrug efflux pump KexD from Klebsiella pneumoniae. Gene. 2012;498(2):177–182.
77. Liu YY, Wang Y, Walsh TR, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016;16(2):161–168.
78. Mohsin M, Raza S, Roschanski N, Guenther S, Ali A, Schierack P. Description of the first Escherichia coli clinical isolate harboring the colistin resistance gene mcr-1 from the Indian subcontinent. Antimicrob Agents Chemother. 2017;61(1).
79. Brooks BD, Brooks AE. Therapeutic strategies to combat antibiotic resistance. Adv Drug Deliv Rev. 2014;78:14–27.
80. Pena-Miller R, Laehnemann D, Jansen G, et al. When the most potent combination of antibiotics selects for the greatest bacterial load: the smile-frown transition. PLoS Biol. 2013;11(4):e1001540.
81. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov. 2007;6(1):29–40.
82. Kalia VC, Wood TK, Kumar P. Evolution of resistance to quorum-sensing inhibitors. Microb Ecol. 2014;68(1):13–23.
83. Baveja JK, Li G, Nordon RE, et al. Biological performance of a novel synthetic furanone-based antimicrobial. Biomaterials. 2004;25(20):5013–5021.
84. Choi S, Isaacs A, Clements D, et al. De novo design and in vivo activity of conformationally restrained antimicrobial arylamide foldamers. Proc Natl Acad Sci U S A. 2009;106(17):6968–6973.
85. Scott RW, Degrado WF, Tew GN. De novo designed synthetic mimics of antimicrobial peptides. Curr Opin Biotechnol. 2008;19(6): 620–627.
86. Weber T. In silico tools for the analysis of antibiotic biosynthetic pathways. Int J Med Microbiol. 2014;304(3–4):230–235.
87. Littmann J, Viens AM. The ethical significance of antimicrobial resistance. Public Health Ethics. 2015;8(3):209–224.
88. Kumar M, Curtis A, Hoskins C. Application of nanoparticle technologies in the combat against anti-microbial resistance. Pharmaceutics. 2018;10(1).
89. Wang L, Hu C, Shao L. The antimicrobial activity of nanoparticles: present situation and prospects for the future. Int J Nanomedicine. 2017;12:1227–1249.
90. Brown KL, Hancock RE. Cationic host defense (antimicrobial) peptides. Curr Opin Immunol. 2006;18(1):24–30.
91. Forde E, Devocelle M. Pro-moieties of antimicrobial peptide prodrugs. Molecules. 2015;20(1):1210–1227.
92. Nguyen LT, Haney EF, Vogel HJ. The expanding scope of antimicrobial peptide structures and their modes of action. Trends Biotechnol. 2011;29(9):464–472.
93. Dangel A, Ackermann N, Abdel-Hadi O, et al. A de novo-designed antimicrobial peptide with activity against multiresistant Staphylococcus aureus acting on RsbW kinase. FASEB J. 2013;27(11):4476–4488.
94. Hao G, Shi YH, Tang YL, Gw L. The intracellular mechanism of action on Escherichia coli of BF2-A/C, two analogues of the antimicrobial peptide Buforin 2. J Microbiol. 2013;51(2):200–206.
95. Ghosh A, Kar RK, Jana J, et al. Indolicidin targets duplex DNA: structural and mechanistic insight through a combination of spectroscopy and microscopy. ChemMedChem. 2014;9(9):2052–2058.
96. Maria-Neto S, de Almeida KC, Macedo ML, Franco OL. Understanding bacterial resistance to antimicrobial peptides: from the surface to deep inside. Biochim Biophys Acta. 2015;1848(11 Pt B):3078–3088.
97. Parachin NS, Franco OL. New edge of antibiotic development: antimicrobial peptides and corresponding resistance. Front Microbiol. 2014;5:147.
98. Abraham EP, Chain E. An enzyme from bacteria able to destroy penicillin. 1940. Rev Infect Dis. 1988;10(4):677–678.
99. Gould IM. Antibiotic resistance: understanding how to control it. Int J Antimicrob Agents. 2012;40(3):193–195.
100. Jain R, Kralovic SM, Evans ME, et al. Veterans Affairs initiative to prevent methicillin-resistant Staphylococcus aureus infections. N Engl J Med. 2011;364(15):1419–1430.
101. Gurieva T, Bootsma MC, Bonten MJ. Successful Veterans Affairs initiative to prevent methicillin-resistant Staphylococcus aureus infections revisited. Clin Infect Dis. 2012;54(11):1618–1620.
102. Wyllie DH, Walker AS, Miller R, et al. Decline of methicillin-resistant Staphylococcus aureus in Oxfordshire hospitals is strain-specific and preceded infection-control intensification. BMJ Open. 2011;1(1):e000160.
103. Sirijatuphat R, Sripanidkulchai K, Boonyasiri A, et al. Implementation of global antimicrobial resistance surveillance system (GLASS) in patients with bacteremia. PLoS One. 2018;13(1):e0190132.
104. Belay ED, Kile JC, Hall AJ, et al. Zoonotic disease programs for enhancing global health security. Emerg Infect Dis. 2017;23(13).
105. Ghafur A, Mathai D, Muruganathan A, et al. The Chennai Declaration: a roadmap to tackle the challenge of antimicrobial resistance. Indian J Cancer. 2013;50(1):71–73.
106. Cantón R, Akóva M, Carmeli Y, et al. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect. 2012;18(5):413–431.
107. Bigdeli M, Jacobs B, Tomson G, et al. Access to medicines from a health system perspective. Health Policy Plan. 2013;28(7): 692–704.
108. Fischbach MA. Combination therapies for combating antimicrobial resistance. Curr Opin Microbiol. 2011;14(5):519–523.
109. Coates AR, Halls G, Hu Y. Novel classes of antibiotics or more of the same? Br J Pharmacol. 2011;163(1):184–194.
110. Infectious Diseases Society of America. The 10×’20 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis. 2010;50(8):1081–1083.
111. Escaich S. Antivirulence as a new antibacterial approach for chemotherapy. Curr Opin Chem Biol. 2008;12(4):400–408.
112. Rex JH, Eisenstein BI, Alder J, et al. A comprehensive regulatory framework to address the unmet need for new antibacterial treatments. Lancet Infect Dis. 2013;13(3):269–275.
113. Research programme: bacteriophage therapeutics – AmpliPhi BioSci-ences/Leicester and Glasgow Universities. Available from: https://adisinsight.springer.com/drugs/800039161. Accessed May 11, 2018.
114. Raqib R, Sarker P, Bergman P, et al. Improved outcome in shigellosis associated with butyrate induction of an endogenous peptide antibiotic. Proc Natl Acad Sci U S A. 2006;103(24):9178–9183.
115. Bergman P, Norlin AC, Hansen S, Björkhem-Bergman L. Vitamin D supplementation to patients with frequent respiratory tract infections: a post hoc analysis of a randomized and placebo-controlled trial. BMC Res Notes. 2015;8:391.
116. Matsuoka O, Patel DM, Sasaki S, et al. Safety and immunogenicity of Clostridium difficile toxoid vaccine in Japanese adults. Hum Vaccin Immunother. 2018;14(2):322–328.
117. Peng Z, Ling L, Stratton CW, et al. Advances in the diagnosis and treatment of Clostridium difficile infections. Emerg Microbes Infect. 2018;7(1):15.
118. NVB 302. Available from: https://adisinsight.springer.com/drugs/800030483. Accessed February 1, 2018.
119. Research programme – plectasin antibacterials – Adenium Biotech. Available from: https://adisinsight.springer.com/drugs/800039698. Accessed February 2, 2018.
120. Hernandez LD, Racine F, Xiao L, et al. Broad coverage of genetically diverse strains of Clostridium difficile by actoxumab and bezlotoxumab predicted by in vitro neutralization and epitope modeling. Antimicrob Agents Chemother. 2015;59(2):1052–1060.
121. Morrison C. Antibacterial antibodies gain traction. Nat Rev Drug Discov. 2015;14(11):737–738.
122. Dubberke ER, Lee CH, Orenstein R, Khanna S, Hecht G, Gerding DN. Results from a randomized placebo-controlled clinical trial of a RBX2660 – a microbiota-based drug for the prevention of recurrent Clostridium difficile infection. Clin Infect Dis. Epub 2018 Mar 29.
123. Seres Therapeutics. SER-109. Available from: http://www.seresthera-peutics.com/clinical-trials/ecospor-trial. Accessed May 11, 2018.
124. Gerding DN, Meyer T, Lee C, et al. Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial. JAMA. 2015;313(17):1719–1727.
125. Begier E, Seiden DJ, Patton M, et al. SA4Ag, a 4-antigen Staphylococcus aureus vaccine, rapidly induces high levels of bacteria-killing antibodies. Vaccine. 2017;35(8):1132–1139.
126. Jun SY, Jung GM, Yoon SJ, et al. Preclinical safety evaluation of intravenously administered SAL200 containing the recombinant phage endolysin SAL-1 as a pharmaceutical ingredient. Antimicrob Agents Chemother. 2014;58(4):2084–2088.
127. Schuch R, Lee HM, Schneider BC, et al. Combination therapy with lysin CF-301 and antibiotic is superior to antibiotic alone for treating methicillin-resistant Staphylococcus aureus-induced murine bacteremia. J Infect Dis. 2014;209(9):1469–1478.
128. Hua L, Hilliard JJ, Shi Y, et al. Assessment of an anti-alpha-toxin monoclonal antibody for prevention and treatment of Staphylococcus aureus-induced pneumonia. Antimicrob Agents Chemother. 2014;58(2):1108–1117.
129. Aridis Pharmaceuticals. AR-301 (Salvecin®). Available from: https://aridispharma.com/ar-301/. Accessed May 11, 2018.
130. Varshney AK, Kuzmicheva GA, Lin J, et al. A natural human monoclonal antibody targeting staphylococcus protein A protects against Staphylococcus aureus bacteremia. PLoS One. 2018;13(1):e0190537.
131. Phase I/II trial of AmpliPhage-001 in patients with cystic fibrosis-associated Pseudomonas aeruginosa infections. Available from: https://adisinsight.springer.com/trials/700252954. Accessed May 11, 2018.
132. Research programme: antibacterial protein-based therapeutics – Phico Therapeutics. Available from: https://adisinsight.springer.com/drugs/800027172. Accessed August 4, 2016.
133. Westritschnig K, Hochreiter R, Wallner G, Firbas C, Schwameis M, Jilma B. A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers. Hum Vaccin Immunother. 2014;10(1):170–183.
134. Labiotech. Swiss pharma clears €37M funding to develop a new class of antibiotics. Available from: https://labiotech.eu/polyphor-murepavadin-pol6014-funding/. Accessed May 11, 2018.
135. Aridis Pharmaceuticals. AR-101 (Aerumab™). Available from: https://aridispharma.com/ar-101/. Accessed May 11, 2018.
136. Aridis Pharmaceuticals. AR-105 (Aerucin®). Available from: https://aridispharma.com/ar-105/. Accessed May 11, 2018.
137. Digiandomenico A, Keller AE, Gao C, et al. A multifunctional bispe-cific antibody protects against Pseudomonas aeruginosa. Sci Transl Med. 2014;6262(262):ra155.